hrcak mascot   Srce   HID

Izvorni znanstveni članak

ADVERSE DRUG REACTIONS OF HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS REPORTED TO AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES

Nikica Mirošević Skvrce
Nada Božina
Viola Macolić Šarinić
Siniša Tomić

Puni tekst: hrvatski, pdf (259 KB) str. 0-0 preuzimanja: 90* citiraj
APA 6th Edition
Mirošević Skvrce, N., Božina, N., Macolić Šarinić, V. i Tomić, S. (2010). NUSPOJAVE INHIBITORA 3-HIDROKSI-3-METIL-GLUTARIL KOENZIM A REDUKTAZE PRIJAVLJENE AGENCIJI ZA LIJEKOVE I MEDICINSKE PROIZVODE. Liječnički vjesnik, 132 (9-10), 0-0. Preuzeto s https://hrcak.srce.hr/171119
MLA 8th Edition
Mirošević Skvrce, Nikica, et al. "NUSPOJAVE INHIBITORA 3-HIDROKSI-3-METIL-GLUTARIL KOENZIM A REDUKTAZE PRIJAVLJENE AGENCIJI ZA LIJEKOVE I MEDICINSKE PROIZVODE." Liječnički vjesnik, vol. 132, br. 9-10, 2010, str. 0-0. https://hrcak.srce.hr/171119. Citirano 23.10.2019.
Chicago 17th Edition
Mirošević Skvrce, Nikica, Nada Božina, Viola Macolić Šarinić i Siniša Tomić. "NUSPOJAVE INHIBITORA 3-HIDROKSI-3-METIL-GLUTARIL KOENZIM A REDUKTAZE PRIJAVLJENE AGENCIJI ZA LIJEKOVE I MEDICINSKE PROIZVODE." Liječnički vjesnik 132, br. 9-10 (2010): 0-0. https://hrcak.srce.hr/171119
Harvard
Mirošević Skvrce, N., et al. (2010). 'NUSPOJAVE INHIBITORA 3-HIDROKSI-3-METIL-GLUTARIL KOENZIM A REDUKTAZE PRIJAVLJENE AGENCIJI ZA LIJEKOVE I MEDICINSKE PROIZVODE', Liječnički vjesnik, 132(9-10), str. 0-0. Preuzeto s: https://hrcak.srce.hr/171119 (Datum pristupa: 23.10.2019.)
Vancouver
Mirošević Skvrce N, Božina N, Macolić Šarinić V, Tomić S. NUSPOJAVE INHIBITORA 3-HIDROKSI-3-METIL-GLUTARIL KOENZIM A REDUKTAZE PRIJAVLJENE AGENCIJI ZA LIJEKOVE I MEDICINSKE PROIZVODE. Liječnički vjesnik [Internet]. 2010 [pristupljeno 23.10.2019.];132(9-10):0-0. Dostupno na: https://hrcak.srce.hr/171119
IEEE
N. Mirošević Skvrce, N. Božina, V. Macolić Šarinić i S. Tomić, "NUSPOJAVE INHIBITORA 3-HIDROKSI-3-METIL-GLUTARIL KOENZIM A REDUKTAZE PRIJAVLJENE AGENCIJI ZA LIJEKOVE I MEDICINSKE PROIZVODE", Liječnički vjesnik, vol.132, br. 9-10, str. 0-0, 2010. [Online]. Dostupno na: https://hrcak.srce.hr/171119. [Citirano: 23.10.2019.]

Sažetak
Hydroxymethylglutaryl-CoA reductase inhibitors (statins) are drugs used in the treatment of chronic diseases and frequently in concomitant therapy with many other drugs. Therefore, the risk of adverse drug reactions (ADRs), especially those caused by interactions is high. Aim of the study was to describe and analyze ADRs caused by statins reported to Croatian Agency from March 2005 to December 2008, and to emphasize reasons of their occurrence. 136 of statin ADRs were reported. 12 % of all reported statins’ ADRs were caused by interactions, which is higher than percent (5.6%) of interactions caused by all other drugs in 2005 and 2006. Proportion of serious ADRs related to administered dose and thus preventable was higher than proportion of all ADRs caused by statins (p=0.003). Most serious ADRs could have been prevented with better understanding of interactions and by use of pharmacogenomics in identifying patients that are because of genetic predisposition more sensitive to standard doses.

Ključne riječi
Hydroxymethylglutaryl-CoA reductase inhibitors – adverse effects, pharmacokinetics, pharmacology; Adverse drug reaction reporting systems – statistics and numerical data; Croatia – epidemiology

Hrčak ID: 171119

URI
https://hrcak.srce.hr/171119

[hrvatski]

Posjeta: 184 *